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Published medical literature forms an ever-expanding 
web of information, available to patients, clinicians and all 
healthcare providers in everyday practice. Data from some 
of these publications, especially from high-impact journals, 
may be used to guide therapeutic decisions. Moreover, 
these data will be used for future studies’ design, such as for 
sample size calculations based on previously published size 
effects (1) or for conducting systematic reviews and meta-
analyses, that represent the highest level of evidence in 
Medical Research (2). Unfortunately, a growing volume of 
evidence suggests high rates of poor selection and reporting 
of research outcomes; the reasons are either inadequate 
formulation of the research question or deliberate selection 
of outcomes presented depending on their observed 
results (outcome reporting bias), but in any case this is a 
rather worrisome phenomenon that needs to be properly 
addressed in order to protect transparency and reliability of 
health care research.
Outcome reporting in medical research and its 
pitfalls
A primary outcome (or endpoint) represents the specific 
research question each study is designed to answer, whereas 
secondary outcomes provide additional potentially relevant 
information that can help with the interpretation of the 
primary outcome. In practice, secondary outcomes are 
most often reported ‘out of nowhere’, without having been 
pre-specified or defined on such rigorous terms as the 
primary endpoint. They are to be interpreted with caution, 
especially in randomized controlled trials (RCTs), as by 
definition the study is sufficiently powered to answer only 
the primary outcome question. Clearly, when conducting 
a research project, especially for high-level studies like 
RCTs, efficiency and scientific rigor is mandatory and 
several data are collected along with the primary outcome 
results, to complete and explain them. But how reliable 
and transparent are these reported outcomes? Outcome 
reporting bias, meaning selective reporting of outcomes 
depending on the results obtained, has been identified as 
a major problem even in well-designed and prestigious 
trials (3). Several studies reviewing the quality of outcome 
reporting in published RCTs emphasized that only 47% of 
trials report the same primary outcome in publication as 
in the initial protocol (4) whereas in 62% of all published 
studies at least one primary outcome was changed, 
downgraded to secondary endpoint, added or completely 
omitted compared to the study protocol (3-5). Moreover, 
it has been repeatedly observed that significant results and 
the presence of external funding interfere greatly with the 
choice of outcomes to be reported in final publication (3,6). 
As shown by the above mentioned studies, the scientific 
community has information about the quality of primary 
outcome reporting, but very little is known about that 
of secondary outcomes, deemed to be even worse (3). 
Furthermore, if endpoint documentation seems so poor 
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for RCTs, where normally a protocol precedes the final 
publication of the trial, what can be deduced about 
observational cohort or registry-based studies, where no 
pre-existing protocol exists? There is no way to know if 
the secondary outcomes were actually planned or not, or 
if they come from ‘data dredging’ or pure reporting bias, 
for example to replace deceiving results of the primary 
outcome. These considerations along with many others 
have lead Glasziou et al. to define several types of ‘research 
waste’, meaning research data that consume a great deal of 
energy and resources from trial planning until publication, 
but remain poorly documented or incomplete, and thus, of 
no value (5,7). 
What does poor outcome reporting mean for 
clinical practice?
Poor outcome reporting, defined here as either reporting 
bias or poor methodology in the definition and detection 
of the reported outcomes, may have serious implications 
both for clinical practice and future research. In addition 
to reducing each study’s internal validity, its effect is 
potentialized when data from such studies are combined 
together in systematic reviews and meta-analyses. The 
PRISMA guidelines of conduct and reporting of systematic 
reviews and meta-analyses, require accurate definition of 
all research questions to be answered on a review level (8). 
However, on an individual study level, although the risk of 
outcome reporting bias can be assessed by different methods 
(e.g., the Cochrane Collaboration tool for assessing risk of 
bias) (9), the actual quality and relevance of the reported 
outcomes may not at all be assessed or reported in the final 
conclusions. As the quality of any meta-analysis can only be 
as good as the individual studies included, caution is needed 
for the interpretation of such high-level information if 
underlying outcome reporting seems to be poor.
In a very insightful recent study, Matthews et al. (10) 
identified another interesting aspect of poor outcome 
reporting, the unreliability of data presented as secondary 
outcomes in RCTs. They assessed the rate of surgical site 
infections (SSIs) reported in several high-impact surgical 
RCTs, and found that irrespective of the type of surgery 
and the level of contamination, when SSIs were reported 
as secondary outcome they were significantly lower, thus 
under-reported, compared to when reported as the primary 
outcome (5.1% vs.12.6% respectively, P<0.001). Definitions 
and detection methods of SSIs were less rigorously followed 
for secondary endpoints, explaining this striking difference. 
The first potential problem here is the danger of 
using misleading information in clinical practice, for 
example when a patient is incorrectly informed about 
his real risk of SSI based on poor quality data. From a 
more scientific point of view, if a future study with SSIs 
as primary endpoint was to be planned, one of these 
baseline estimations of SSI may be used for sample 
size calculation For example, if a study was planned 
for an intervention X that will decrease the rate of 
postoperative SSIs by 50%, in the first case (baseline SSI 
=5.1%), 2 groups of 905 patients each will be needed, 
whereas in the second case (baseline SSI =12.6%), only 
377 patients per group are required for a power of 80% 
and an alpha-error of 0.05 (11). Of course, while planning 
such a study, the author will seek the most reliable and 
widely accepted baseline SSI rate, but this is a typical 
situation where previously published ‘research waste’, re-
used without the necessary critical appraisal, might lead to 
a real waste of resources in future research.
Increasing rigor in outcome reporting; core 
outcome sets (COS) and research guidelines
As awareness is rising in recent years about methodological 
problems related to outcome reporting described above, 
several initiatives have been taken to improve reliability and 
transparency of research results. 
To specifically address the problem of poor outcome 
reporting, the COS has been developed for many fields 
of medical research. The COMET initiative (Core 
Outcome Measures in Effectiveness Trials) launched the 
process in 2012, to improve both the clinical relevance and 
transparency of research outcomes reported in published 
studies (12). As significant heterogeneity is observed in 
the types of outcomes authors choose to study and report, 
development of standardized sets of clinically relevant 
outcomes for specific research fields are a valuable option. 
The COMET database currently contains 857 references 
of planned, ongoing and completed work (13) while any 
researcher can develop a new set of outcomes deemed 
relevant and reproducible for his field of interest (14). 
Basically, by defining a standard minimum of outcomes to 
report in each study, several advantages might be expected; 
less missing data on key outcome measures, complete and 
rigorous description of the outcomes concerning a field of 
interest, ensuring the report of clinically relevant outcomes 
in each research question, and as a result, limiting the risk 
of outcome reporting bias.
Annals of Translational Medicine, Vol 5, Suppl 1 May 2017 Page 3 of 4
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2017;5(Suppl 1):S15atm.amegroups.com
The EQUATOR initiative (Enhancing the QUAlity 
and Transparency Of Research results), funded in 2006 
by Douglas Altman’s team in Oxford (15), is another 
pioneer movement aiming to improve and standardize the 
way medical research is conducted and reported. Today, 
guidelines and checklists have been developed for all major 
study types, such as the CONSORT reporting guidelines 
for RCTs, STROBE for observational studies, PRISMA 
for systematic review and meta-analyses, SPIRIT for 
study protocols etc. These guidelines are freely available 
for researchers (15) and can be of great help both while 
planning the study and drafting the manuscript. Many 
high-impact journals require conformity of the manuscript 
with the above standards to accept submitted manuscripts, 
however the overall adherence to these guidelines has been 
reported as low as 20% of published studies (16). Thus, 
ongoing effort is required from both medical journals and 
individual researchers to ensure a maximal adherence to 
these guidelines, leading to increased scientific rigor and 
reproducibility of results (5).
Pre-publication registration of all studies, especially 
those with a high expected impact, provides a valuable tool 
of methodological assessment of published trials. Internet-
based registries already exist for RCTs (www.ClinicalTrials.
gov, European Clinical Trials Database–EudraCT) 
and systematic reviews/ meta-analyses (PROSPERO 
registry) (17). Although registration of those key study 
types allows some control over the potential risks of bias, 
observational studies remain a major unsolved problem. As 
mentioned above, there is no way of controlling potential 
outcome-related bias in these studies, due to no pre-existing 
study plan for comparison. Increasing attention is paid to 
the need of registration and monitoring of observational 
studies, however to this day nothing has yet changed in this 
direction (18,19). 
In conclusion, poor outcome reporting is getting 
increased attention from both statisticians and researchers 
in recent years, with alarming rates of inadequate outcome 
measures published even in high-impact literature. 
Acknowledging the problem already leads to the necessary 
cautious interpretation of published study results, however 
the real need is taking outcome reporting to a better level. 
Development and use of COS, transparent registration of 
trials and adherence to standardized guidelines of study 
report are some extremely valuable, although clearly 
underused tools, that should be rigorously implemented 
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